MRC1 and colorectal carcinoma: The study showed a significantly reduced risk of recurrence for MMR-deficient CRC (risk ratio, 0.53, 95% C.I., 0.40–0.70; p < 0.001) as compared to proficient ones, and the subanalysis for MMR status demonstrated no benefit from adjuvant chemotherapy [74].